ABBV-576

DRUG2 trials

Sponsors

AbbVie

Conditions

Cystic Fibrosis (CF)Healthy Volunteers

Phase 1

A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis

CompletedNCT05530278

AbbVieHealthy Volunteers

Start: 2022-09-20End: 2022-11-29Updated: 2023-02-21

Phase 2

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

TerminatedNCT04853368

AbbVieCystic Fibrosis (CF)

Start: 2021-09-20End: 2023-06-05Updated: 2024-07-16